Arcutis Biotherapeutics Inc Cash Flow Conversion Efficiency
Arcutis Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has a cash flow conversion efficiency ratio of 0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($12.64 Million) by net assets ($220.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Arcutis Biotherapeutics Inc (2017–2025)
Cash flow conversion efficiency of Arcutis Biotherapeutics Inc from 2017 to 2025. This chart illustrates how Arcutis Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Arcutis Biotherapeutics Inc (ARQT) stock price for real-time trading data and today's change.
Arcutis Biotherapeutics Inc Cash Flow Conversion Ratio Explained
Arcutis Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Arcutis Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see Arcutis Biotherapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
0.005x |
|
Hilton Grand Vacations Inc
NYSE:HGV
|
0.095x |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
0.033x |
|
First Hawaiian Inc
NASDAQ:FHB
|
0.005x |
|
Escorts Kubota Limited
NSE:ESCORTS
|
0.040x |
|
Park National Corporation
NYSE MKT:PRK
|
0.043x |
|
Freshpet Inc
NASDAQ:FRPT
|
0.036x |
|
BankUnited Inc
NYSE:BKU
|
0.043x |
Annual Cash Flow Conversion Efficiency for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Arcutis Biotherapeutics Inc from 2017 to 2025. Review ARQT free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.48 Million | $-5.62 Million | -0.030x | +95.83% |
| 2024-12-31 | $157.54 Million | $-112.16 Million | -0.712x | +74.45% |
| 2023-12-31 | $88.67 Million | $-247.06 Million | -2.786x | -126.59% |
| 2022-12-31 | $209.58 Million | $-257.71 Million | -1.230x | -109.61% |
| 2021-12-31 | $297.68 Million | $-174.63 Million | -0.587x | -40.45% |
| 2020-12-31 | $270.62 Million | $-113.03 Million | -0.418x | +1.07% |
| 2019-12-31 | $101.46 Million | $-42.84 Million | -0.422x | -171.90% |
| 2018-12-31 | $-23.99 Million | $-14.09 Million | 0.587x | -22.33% |
| 2017-12-31 | $-4.99 Million | $-3.77 Million | 0.756x | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more